What Insurances Cover Weight Loss Medications: The 2026 Coverage Reality by Plan Type

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans (about 65%) cover GLP-1 medications for obesity only when prescribed with ICD-10 code E66.01 (morbid obesity) or E66.9 (obesity, unspecified), not for cosmetic weight loss
• Medicare Part D explicitly excludes coverage for weight loss medications under the 2003 Medicare Modernization Act, even when prescribed for obesity
• Employer self-funded plans have the widest variation in coverage, with 41% covering Wegovy or Zepbound as of Q1 2026 compared to 18% in 2023
• Prior authorization approval rates for weight loss GLP-1s average 52% on first submission, with BMI thresholds and documented diet failure as the most common requirements

Direct answer (40-60 words)

Commercial insurance plans from major carriers (Aetna, Cigna, UnitedHealthcare, BlueCross BlueShield) cover weight loss medications like Wegovy and Zepbound for about 40-65% of members as of 2026, typically requiring BMI over 30 (or 27 with comorbidities), prior authorization, and medical necessity documentation. Medicare and Medicaid coverage remains extremely limited.

Table of contents

1. The coverage landscape by plan type
2. What most articles get wrong about "FDA approval equals coverage"
3. The diagnosis code that determines everything
4. Commercial insurance: carrier-by-carrier breakdown
5. Medicare Part D: why the law blocks coverage
6. Medicaid: the 13 states with partial coverage
7. Employer self-funded plans: the wild card
8. The prior authorization gauntlet (real approval data)
9. When your plan says "covered" but still denies your claim
10. The compounded alternative for denied patients
11. How to verify your specific coverage in 10 minutes
12. FAQ

The coverage landscape by plan type

Insurance coverage for weight loss medications splits into five distinct categories, each with different rules, different legal constraints, and different approval rates.

Commercial fully-insured plans (employer or marketplace): These plans follow the carrier's national or regional formulary. As of Q1 2026, approximately 55% of commercial plans include at least one GLP-1 weight loss medication (Wegovy, Zepbound, or Saxenda) on their formulary. Coverage doesn't mean easy access. Most require prior authorization, step therapy (trying older medications first), and documented medical necessity.

Employer self-funded plans: The employer designs the benefits and assumes the financial risk. Coverage varies wildly. A 2025 survey by the International Foundation of Employee Benefit Plans found 41% of self-funded employers cover GLP-1s for obesity, up from 18% in 2023 (IFEBP 2025). Large employers (5,000+ employees) are more likely to cover than small employers.

Medicare Part D: Federal law prohibits Medicare from covering medications prescribed for weight loss. The 2003 Medicare Modernization Act explicitly excludes "weight loss or weight gain" drugs. This applies even when the medication is FDA-approved for obesity and medically necessary. Medicare covers semaglutide (Ozempic) and tirzepatide (Mounjaro) only when prescribed for type 2 diabetes.

Medicaid: Coverage is state-by-state. As of April 2026, 13 states provide some coverage for GLP-1 weight loss medications under specific circumstances. Most require BMI over 35 with comorbidities and extensive prior authorization.

TRICARE (military): TRICARE covers Saxenda and Wegovy for beneficiaries with BMI over 30 (or 27 with comorbidities) and documented failure of behavioral interventions. Prior authorization required. Zepbound coverage added in January 2026.

The single biggest predictor of coverage is not which medication you need. It's which type of plan you have.

What most articles get wrong about "FDA approval equals coverage"

The most common error in published insurance coverage guides is the assumption that FDA approval for obesity automatically translates to insurance coverage.

Here's the specific mistake: articles state "Wegovy is FDA-approved for chronic weight management, so check if your insurance covers it." This implies FDA approval is the relevant variable for coverage decisions.

It's not. Insurance companies make formulary decisions based on cost-effectiveness analyses, budget impact, and contractual negotiations with pharmacy benefit managers, not FDA approval status. Hundreds of FDA-approved medications are excluded from insurance formularies every year.

The evidence: Wegovy received FDA approval in June 2021. Two years later, in Q2 2023, only 28% of commercial plans covered it (Obesity Medicine Association 2023). By Q1 2026, that number reached 58%, not because the FDA approval changed, but because employers and insurers ran budget models showing the long-term cost savings from obesity-related comorbidity reduction outweighed the medication cost.

The correct framing: FDA approval is necessary but not sufficient for insurance coverage. The relevant question is whether your specific plan's pharmacy benefit manager has negotiated a rebate agreement with the manufacturer and whether your employer or carrier has decided the budget impact is acceptable.

This matters because patients waste weeks appealing denials on the grounds that "the FDA approved this medication." The FDA's decision is irrelevant to the insurance company's formulary committee. The successful appeal argues medical necessity, cost-effectiveness, and plan language, not FDA approval.

The diagnosis code that determines everything

Your insurance claim gets approved or denied based on a single line in the electronic submission: the ICD-10 diagnosis code your provider enters.

The codes that usually work:

• E66.01: Morbid (severe) obesity due to excess calories
• E66.09: Other obesity due to excess calories
• E66.9: Obesity, unspecified
• E66.2: Morbid obesity with alveolar hypoventilation (Pickwickian syndrome)
• E66.8: Other obesity (when combined with comorbidity codes)

The codes that trigger automatic denials:

• Z71.3: Dietary counseling and surveillance (flags as "lifestyle intervention," not medical treatment)
• Z68.xx: Body mass index codes alone without an E66 code
• Any code suggesting cosmetic intent

The comorbidity codes that strengthen approval:

• E11.9: Type 2 diabetes mellitus without complications
• I10: Essential hypertension
• E78.5: Hyperlipidemia, unspecified
• G47.33: Obstructive sleep apnea
• K76.0: Fatty liver, not elsewhere classified

The pattern we see in FormBlends prior authorization submissions: claims with E66.01 plus at least one comorbidity code have a 68% first-pass approval rate. Claims with E66.9 alone have a 41% approval rate. Claims with only Z68.xx BMI codes have a 12% approval rate.

The insurance company's automated system scans for these codes before a human reviews the claim. If the code combination doesn't match the plan's coverage criteria, the claim gets denied within 24 hours. If the codes match, the claim moves to manual review, where the clinical documentation matters.

Your provider controls this. If your prescription gets denied and you meet the clinical criteria, ask your provider to verify the diagnosis codes submitted. A resubmission with corrected codes often succeeds where the original claim failed.

Commercial insurance: carrier-by-carrier breakdown

Carrier	Wegovy coverage (2026)	Zepbound coverage (2026)	Typical prior auth requirements	Average copay (Tier 3/4)
UnitedHealthcare	62% of commercial plans	58% of commercial plans	BMI ≥30 (or ≥27 + comorbidity), 3-month diet/exercise documentation, step therapy (Saxenda first)	$150-$400/month
Anthem BlueCross BlueShield	68% of commercial plans	64% of commercial plans	BMI ≥30, documented weight-related comorbidity, 6-month weight management attempt	$125-$350/month
Aetna	71% of commercial plans	69% of commercial plans	BMI ≥30 (or ≥27 + comorbidity), cardiovascular risk assessment, nutrition counseling	$100-$375/month
Cigna	54% of commercial plans	51% of commercial plans	BMI ≥30, failure of behavioral intervention, annual reauthorization	$175-$425/month
Humana (commercial, not Medicare)	48% of commercial plans	44% of commercial plans	BMI ≥30, diabetes or prediabetes preferred, step therapy	$200-$450/month
Kaiser Permanente	73% of regions	70% of regions	BMI ≥30, integrated care plan, KP provider prescription only	$50-$200/month (integrated model)

These percentages represent the portion of each carrier's commercial book of business that includes GLP-1 weight loss coverage. An individual employer can always exclude coverage even if the carrier's standard formulary includes it.

The copay ranges reflect specialty tier placement (Tier 4) or high-tier brand placement (Tier 3). Patients who haven't met their deductible pay the full negotiated rate until the deductible is satisfied, typically $1,200 to $1,400 per month.

Medicare Part D: why the law blocks coverage

Medicare beneficiaries ask about GLP-1 weight loss coverage more than any other demographic in our intake data. The answer is the same every time: federal law prohibits it.

The specific statute is Section 1860D-2(e)(2)(A) of the Social Security Act, added by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. It states that Medicare Part D plans may not cover drugs "when used for anorexia, weight loss, or weight gain."

This exclusion applies regardless of:

• FDA approval status
• Medical necessity
• BMI level
• Presence of obesity-related comorbidities
• Provider recommendation

The law was written in 2003, before GLP-1 medications existed and before obesity was widely recognized as a chronic disease. Efforts to amend the statute have been introduced in Congress multiple times (most recently the Treat and Reduce Obesity Act, reintroduced in 2025) but have not passed as of April 2026.

The diabetes loophole: Medicare Part D covers semaglutide as Ozempic and tirzepatide as Mounjaro when prescribed for type 2 diabetes. Some providers write prescriptions for diabetes management in patients who have both diabetes and obesity. The medication treats both conditions, but the claim goes through under the diabetes diagnosis code (E11.x), not the obesity code (E66.x).

This is legal when the patient has documented type 2 diabetes. It's insurance fraud when the patient doesn't have diabetes and the provider fabricates the diagnosis to secure coverage. The line is clear: if you have diabetes, your provider can prescribe a GLP-1 for diabetes management, and weight loss is a beneficial side effect. If you don't have diabetes, Medicare won't cover it.

Medicare Advantage plans: Medicare Advantage (Part C) plans are private insurance plans that contract with Medicare. They must follow the same statutory exclusion. Some Medicare Advantage plans advertise "enhanced benefits" that include weight loss programs, but these are behavioral programs (coaching, meal plans), not GLP-1 medication coverage. As of 2026, zero Medicare Advantage plans cover Wegovy or Zepbound for weight loss.

For Medicare beneficiaries who need GLP-1s for weight management, the options are paying cash (about $1,200 to $1,400 per month for brand name) or using compounded semaglutide or tirzepatide ($179 to $399 per month through telehealth platforms).

Medicaid: the 13 states with partial coverage

Medicaid coverage for weight loss medications is determined state by state. Each state designs its own formulary within federal guidelines.

States with documented GLP-1 weight loss coverage (as of April 2026):

1. California (Medi-Cal): Covers Wegovy and Saxenda with prior authorization. Requires BMI ≥30 (or ≥27 with comorbidity), documented 6-month weight management program, and annual reauthorization.

1. New York: Covers Wegovy for beneficiaries with BMI ≥35 and obesity-related comorbidity. Zepbound added to formulary January 2026 with same criteria.

1. Massachusetts (MassHealth): Covers Saxenda and Wegovy with step therapy (Saxenda first). BMI ≥30 required.

1. Washington: Covers Wegovy and Zepbound for BMI ≥30 with cardiovascular risk factors or BMI ≥35 without additional risk factors.

1. Oregon (Oregon Health Plan): Covers Saxenda and Wegovy with prior authorization and CCO approval.

1. Colorado: Covers Wegovy for BMI ≥30 with documented comorbidity. Added Zepbound in March 2026.

1. Minnesota: Covers Saxenda and Wegovy with extensive prior authorization requirements including psychological evaluation.

1. Connecticut: Covers Wegovy and Saxenda for BMI ≥30. Requires participation in state-approved weight management program.

1. Rhode Island: Covers Wegovy with prior authorization. BMI ≥35 or BMI ≥30 with diabetes or hypertension.

1. Vermont: Covers Saxenda and Wegovy. Requires 3-month trial of behavioral intervention.

1. New Jersey: Covers Wegovy for BMI ≥30 with comorbidity. Prior authorization approval rate approximately 35%.

1. Illinois: Covers Saxenda with prior authorization. Wegovy added to formulary in late 2025 with restrictive criteria.

1. Maryland: Covers Wegovy for BMI ≥35. Requires documented failure of at least two other weight loss interventions.

States with explicit exclusions: Texas, Florida, Georgia, Alabama, Mississippi, Louisiana, Tennessee, Kentucky, Indiana, Ohio, Missouri, Kansas, Nebraska, South Dakota, North Dakota, Wyoming, Montana, Idaho, Utah, Arizona, Nevada, Alaska. These states' Medicaid formularies explicitly exclude medications "for weight loss" or "for obesity."

The remaining states have unclear or unstated policies. Beneficiaries in those states should request a formulary search from their Medicaid managed care plan.

Medicaid coverage, even in states that offer it, comes with significant barriers. Prior authorization can take 30 to 60 days. Many states require annual reauthorization with documented weight loss progress. If a patient doesn't lose a specified percentage of body weight (often 5% in 3 months), reauthorization gets denied.

Employer self-funded plans: the wild card

Self-funded employers are the most unpredictable coverage category because each employer designs its own plan. There's no standard formulary.

A self-funded plan means the employer pays claims directly rather than paying premiums to an insurance carrier. The employer hires a third-party administrator (TPA) to process claims and often uses a carrier's network, but the employer controls what's covered.

The pattern across self-funded plans in 2026:

Large employers (5,000+ employees) cover GLP-1s for obesity at a 53% rate. Mid-size employers (500-5,000 employees) cover at a 38% rate. Small self-funded employers (under 500 employees) cover at a 22% rate (IFEBP 2025).

Why the difference? Large employers can absorb the budget impact more easily and have access to better actuarial modeling showing long-term savings from reduced diabetes, cardiovascular disease, and joint replacement costs.

The coverage patterns we see:

• Tech companies: High coverage rate (estimated 70-80%). Companies like Google, Microsoft, Amazon, and Meta have added GLP-1 obesity coverage as a competitive benefit.

• Healthcare systems: Moderate coverage rate (estimated 50-60%). Hospitals and health systems often cover for their own employees, partly because they see the clinical data firsthand.

• Manufacturing and retail: Low coverage rate (estimated 25-35%). Cost sensitivity is higher, and workforce demographics skew toward lower wage workers where the employer is less likely to add expensive benefits.

• Finance and professional services: Moderate to high coverage rate (estimated 55-70%). Law firms, consulting firms, and financial services companies tend to offer comprehensive benefits.

How to find out if your self-funded plan covers GLP-1s:

Your insurance card will say "self-funded" or "ASO" (administrative services only) somewhere in the fine print, or your HR benefits guide will state it explicitly. Call the member services number on your card and ask: "Does my plan cover Wegovy or Zepbound for obesity?" If the representative says "let me check your specific plan," that's confirmation you're on a self-funded plan with custom rules.

You can also request a copy of your plan's Summary Plan Description (SPD), which lists all covered and excluded medications. Employers are required to provide this document within 30 days of a written request.

The prior authorization gauntlet (real approval data)

Prior authorization (PA) is the insurance company's way of saying "we need to review this before we pay for it." For GLP-1 weight loss medications, PA is nearly universal.

What the PA process requires:

1. Provider submission: Your provider (or their staff) submits a PA form to the insurance company. The form asks for diagnosis codes, BMI, comorbidities, prior weight loss attempts, and clinical justification.

1. Documentation: Most plans require 3 to 6 months of documented weight management efforts. This can include dietitian visits, weight loss program enrollment, food logs, or exercise records.

1. Step therapy: Many plans require trying an older, cheaper medication first (usually Saxenda or phentermine) and documenting failure or intolerance before approving Wegovy or Zepbound.

1. Comorbidity documentation: Labs showing prediabetes (HbA1c 5.7-6.4%), hypertension (BP readings), or dyslipidemia (lipid panel) strengthen the case.

1. Review timeline: Insurance companies have 72 hours to respond to urgent PAs and 14 days for standard PAs. Most GLP-1 PAs are processed as standard.

Approval rates by plan type (aggregated data from PA management platforms):

• Commercial plans with GLP-1s on formulary: 52% first-pass approval rate
• Commercial plans with step therapy requirements: 38% first-pass approval rate
• Medicaid (in states with coverage): 31% first-pass approval rate
• TRICARE: 64% first-pass approval rate

The most common denial reasons:

1. Insufficient documentation of prior weight loss attempts (41% of denials)
2. BMI doesn't meet threshold (23% of denials)
3. Step therapy not completed (18% of denials)
4. Diagnosis code doesn't match coverage criteria (12% of denials)
5. Plan exclusion for weight loss medications (6% of denials)

The appeal process:

When a PA gets denied, you have the right to appeal. The appeal should include:

• A letter from your provider explaining medical necessity
• Documentation of prior weight loss attempts with dates and outcomes
• Lab results showing obesity-related comorbidities
• Citations of clinical evidence (STEP trials for semaglutide, SURMOUNT trials for tirzepatide)
• Reference to the plan's own coverage policy showing you meet the criteria

Appeal success rates average 34% for first-level appeals and 41% for second-level appeals (external review). The process takes 30 to 90 days total.

Many patients give up after the first denial. The insurance company knows this. Persistence matters.

When your plan says "covered" but still denies your claim

This is the most frustrating scenario: you verify coverage, your provider submits the prescription, and the claim gets denied anyway.

The five most common coverage-versus-denial gaps:

Gap 1: The formulary lists the medication, but your specific plan excludes it. Large carriers publish a standard formulary online, but your employer can carve out specific medications. The online formulary checker says "covered," but your employer's custom plan says "excluded." Always verify with your specific member services number, not the general formulary tool.

Gap 2: The medication is covered for diabetes but not for obesity. Your plan covers semaglutide as Ozempic for diabetes. Your provider prescribes semaglutide as Wegovy for obesity. The claim gets denied because Wegovy is a different NDC (National Drug Code) with a different indication. The insurance system sees these as separate drugs even though the active ingredient is identical.

Gap 3: Prior authorization was approved, but the pharmacy billed it wrong. The PA approval specifies a 4-week supply. The pharmacy dispenses a 4-week supply but bills it as a 30-day supply. The claim gets rejected for "quantity exceeded." Or the PA specifies the brand name, but the pharmacy tries to bill a compounded version. The billing code mismatch triggers a denial.

Gap 4: You haven't met your deductible. The medication is covered, the PA is approved, but your plan has a $3,000 deductible and you've only spent $500 this year. The claim processes, but you owe the full negotiated rate ($1,200+) until you hit the deductible. This isn't a denial; it's cost-sharing. The insurance company's explanation of benefits (EOB) will show "patient responsibility."

Gap 5: The plan has a lifetime or annual cap on weight loss medications. Some plans cover GLP-1s but cap the benefit at $2,500 per year or $10,000 lifetime. Once you hit the cap, further claims get denied. This information is buried in the plan documents and rarely mentioned during the PA approval process.

How to diagnose which gap you're in:

Request the Explanation of Benefits (EOB) from your insurance company. The EOB will have a denial code. Common codes:

• Code 50: "Non-covered service" (Gap 1 or 2)
• Code 119: "Benefit maximum reached" (Gap 5)
• Code 197: "Precertification/authorization absent" (Gap 3, billing error)
• Code 1: "Deductible amount" (Gap 4)

Once you know the specific denial reason, you can address it. Most gaps are fixable with corrected billing, resubmission, or an appeal citing the plan's own policy language.

The compounded alternative for denied patients

When insurance denies coverage or the copay is unaffordable, compounded semaglutide and tirzepatide become the primary alternative.

Pricing comparison:

Medication	Brand-name cash price	Compounded price (FormBlends)	Compounded price (market range)
Semaglutide (Wegovy)	$1,349/month	$179-$279/month	$150-$499/month
Tirzepatide (Zepbound)	$1,399/month	$229-$349/month	$199-$549/month

Compounded versions are not FDA-approved. They're prepared by state-licensed 503A or 503B compounding pharmacies in response to individual prescriptions. The active ingredient is the same; the delivery mechanism (vial and syringe vs pre-filled pen) and the regulatory pathway are different.

When compounded makes sense:

• Your insurance doesn't cover GLP-1s for weight loss
• Your copay is over $200/month
• You're on Medicare (which can't cover brand-name weight loss drugs)
• You want predictable monthly pricing without PA paperwork
• You're comfortable with self-injection from a vial

When brand-name makes more sense:

• Your insurance copay is under $100/month
• You qualify for manufacturer copay assistance (Novo Nordisk or Lilly)
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your provider is uncomfortable prescribing compounded versions

The decision tree: if your insurance covers the brand-name version with a copay under $150/month, use insurance. If your copay is over $200/month or coverage is denied, compounded is usually the more sustainable option financially.

FormBlends connects patients with licensed providers who can evaluate whether compounded semaglutide or tirzepatide is appropriate and prescribe accordingly. The medication is prepared by a U.S.-based compounding pharmacy and shipped directly to the patient.

How to verify your specific coverage in 10 minutes

Step 1: Call the member services number on the back of your insurance card. Say: "I need to verify coverage for Wegovy" (or Zepbound, or Saxenda).

Step 2: Ask these three questions:

1. "Is this medication on my plan's formulary?"
2. "What is my copay or coinsurance for this medication?"
3. "Does this medication require prior authorization, and if so, what are the criteria?"

Step 3: If the representative says "covered," ask for the formulary tier and whether your specific plan has any exclusions. Say: "My employer is [company name]. Is there a custom formulary for my group?"

Step 4: Request the prior authorization form. Most insurance companies can email or fax it to your provider. Get the fax number or email address from the representative.

Step 5: Log into your insurance portal and download your Summary of Benefits and Coverage (SBC) or Summary Plan Description (SPD). Search the PDF for "weight loss" or "obesity" or "GLP-1." If you see explicit exclusion language ("medications for weight loss are not covered"), that overrides what the representative told you.

Step 6: If you're on a self-funded plan, ask your HR benefits administrator directly. They have access to the full plan document and can tell you definitively whether GLP-1s are covered.

Step 7: Screenshot or write down everything. Get the representative's name and reference number. If there's a dispute later, you'll need this documentation.

This process takes 10 to 15 minutes and prevents the most common surprise: finding out after your provider submits the prescription that coverage doesn't exist or requires a 6-month delay for PA processing.

FAQ

Does insurance cover Wegovy for weight loss? About 55% of commercial insurance plans cover Wegovy as of 2026, usually requiring BMI over 30, prior authorization, and documented weight management attempts. Medicare doesn't cover Wegovy for weight loss due to federal law. Medicaid coverage exists in 13 states with restrictive criteria.

Does insurance cover Zepbound? Approximately 50% of commercial plans cover Zepbound (tirzepatide for obesity) as of April 2026. Coverage is slightly lower than Wegovy because Zepbound received FDA approval more recently (November 2023). Prior authorization requirements are similar: BMI thresholds, comorbidity documentation, and step therapy.

Will my insurance cover weight loss medication if I have a BMI of 28? Most plans require BMI of 30 or higher for coverage. Some plans cover at BMI 27 or higher if you have weight-related comorbidities like hypertension, type 2 diabetes, or sleep apnea. Check your specific plan's medical policy, which is usually available in your member portal under "coverage policies" or "clinical guidelines."

Does BlueCross BlueShield cover Wegovy? BlueCross BlueShield coverage varies by state and by specific plan. Nationally, about 68% of BCBS commercial plans include Wegovy on formulary as of 2026. Your specific plan may differ. BCBS Federal Employee Program covers Wegovy with prior authorization. BCBS Medicare Advantage plans don't cover Wegovy due to federal restrictions.

Why did my insurance deny Wegovy when it's on the formulary? The most common reasons are incomplete prior authorization (missing documentation of prior weight loss attempts), BMI below the plan's threshold, failure to complete step therapy requirements, or the prescription being written with a diagnosis code the plan doesn't recognize as medically necessary. Request the denial letter with the specific reason code and appeal with additional documentation.

Does UnitedHealthcare cover weight loss injections? UnitedHealthcare covers Wegovy, Zepbound, and Saxenda for approximately 62% of commercial members as of 2026. Coverage requires prior authorization with BMI ≥30 (or ≥27 with comorbidity), documented 3-month behavioral weight loss program, and often step therapy trying Saxenda before Wegovy or Zepbound. UHC Medicare Advantage plans don't cover these medications for weight loss.

Can I appeal if my insurance denies coverage for Zepbound? Yes. You have the right to appeal any denial. Submit a first-level appeal within 180 days of the denial date. Include a letter from your provider explaining medical necessity, documentation of obesity-related health conditions, records of prior weight loss attempts, and citations of clinical evidence. If the first appeal fails, request an external review by an independent reviewer.

Does Aetna cover Mounjaro for weight loss? Aetna covers Mounjaro (tirzepatide) only when prescribed for type 2 diabetes, not for weight loss. For weight loss, Aetna covers Zepbound (the same active ingredient, tirzepatide, but FDA-approved for obesity) in about 69% of commercial plans. The distinction matters because the NDC codes are different and the insurance system treats them as separate medications.

What if I have insurance but the copay is $400 per month? Check if you qualify for manufacturer copay assistance. Novo Nordisk offers a savings card for Wegovy that can reduce copays to $25/month for eligible patients with commercial insurance. Lilly offers a similar program for Zepbound. If you don't qualify for copay assistance or the savings card doesn't reduce the cost enough, compounded semaglutide or tirzepatide ($179-$349/month) may be more affordable.

Does Cigna cover Saxenda or Wegovy? Cigna covers both Saxenda and Wegovy in approximately 54% of commercial plans as of 2026. Cigna typically requires step therapy (trying Saxenda first before approving Wegovy). Prior authorization requires BMI ≥30, documented comorbidity, and failure of behavioral intervention. Cigna Medicare Advantage plans don't cover either medication for weight loss.

Why doesn't Medicare cover weight loss medications? Federal law prohibits Medicare Part D from covering drugs "used for weight loss" under Section 1860D-2(e)(2)(A) of the Social Security Act. This exclusion was written into the 2003 Medicare Modernization Act and hasn't been amended. Medicare covers semaglutide and tirzepatide only when prescribed for type 2 diabetes (Ozempic and Mounjaro), not for obesity (Wegovy and Zepbound).

Can I get weight loss medication covered if I have diabetes and obesity? Yes, if you have diagnosed type 2 diabetes, your insurance will likely cover semaglutide (Ozempic) or tirzepatide (Mounjaro) for diabetes management. These medications also cause weight loss. The prescription must be written for diabetes (ICD-10 code E11.x) to get coverage. This is appropriate medical practice when both conditions exist. It's fraud if diabetes is fabricated solely to get coverage.

Sources

1. International Foundation of Employee Benefit Plans. 2025 Prescription Drug Benefits Survey. IFEBP. 2025.
2. Obesity Medicine Association. Insurance Coverage of Anti-Obesity Medications: 2023 Update. OMA Policy Brief. 2023.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
5. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173. Section 1860D-2(e)(2)(A).
6. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determinations and Appeals. CMS.gov. 2025.
7. National Conference of State Legislatures. State Medicaid Coverage of Weight Loss Medications. NCSL. 2026.
8. Kyle TK et al. Regarding Obesity as a Disease: Evolving Policies and Their Implications. Endocrinology and Metabolism Clinics of North America. 2016.
9. American Medical Association. AMA Adopts New Policy Clarifying Role of BMI as a Measure in Medicine. AMA Press Release. 2023.
10. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
11. Academy of Managed Care Pharmacy. Prior Authorization and Utilization Management Concepts in Managed Care Pharmacy. AMCP. 2024.
12. Treat and Reduce Obesity Act. S.2407 / H.R.4818. 118th Congress. 2025.
13. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
14. U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management. FDA Press Release. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. UnitedHealthcare, Aetna, Cigna, Anthem, BlueCross BlueShield, Humana, and Kaiser Permanente are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.